Marker Therapeutics, Inc.

Tagged: rick kenney

TapImmune Appoints Richard Kenney, M.D., F.A.C.P., as Acting Chief Medical Officer

Dr. Kenney will continue to manage the Company’s ongoing and planned clinical programs for its novel, multi-epitope, T-cell vaccine candidates.

Read More